依那西普与甲氨蝶呤单药或联合治疗银屑病关节炎:随机对照III期试验主要结果
这项双盲随机对照III期试验纳入851例银屑病关节炎患者,比较口服甲氨蝶呤20mg单药、皮下依那西普50mg单药及两药联合治疗24周的疗效。结果显示依那西普单药和联合治疗在ACR20和MDA应答率上均显著优于甲氨蝶呤单药,且两种依那西普方案在48周影像学进展方面均优于甲氨蝶呤单药;联合治疗较依那西普单药未整体提升疗效。
要点
- 依那西普单药与联合方案在24周ACR20和MDA应答均显著优于甲氨蝶呤单药。
- 依那西普单药与联合方案在48周影像学进展均少于甲氨蝶呤单药。
- 联合治疗与依那西普单药整体疗效相似,仅部分皮肤终点不同。
核心结论
- 在银屑病关节炎患者中,依那西普单药及依那西普联合甲氨蝶呤的ACR20、MDA应答和影像学进展控制均优于甲氨蝶呤单药。
- 联合甲氨蝶呤并未整体提高依那西普的疗效。
研究设计与样本
- 双盲随机对照III期试验,共纳入851例银屑病关节炎患者。
- 患者随机分为三组:口服甲氨蝶呤20mg每周联合皮下安慰剂(n=284)、皮下依那西普50mg每周联合口服安慰剂(n=284)、皮下依那西普50mg联合口服甲氨蝶呤20mg每周(n=283)。
- 主要终点为第24周ACR20应答,关键次要终点为第24周MDA应答。
主要发现
- 第24周ACR20应答率:依那西普单药组60.9% vs 甲氨蝶呤单药组50.7%(P=0.029)。
- 第24周MDA应答率:依那西普单药组35.9% vs 甲氨蝶呤单药组22.9%(P=0.005)。
- 第24周ACR20应答率:联合治疗组65.0% vs 甲氨蝶呤单药组50.7%(P=0.005)。
- 第24周MDA应答率:联合治疗组35.7% vs 甲氨蝶呤单药组22.9%(P=0.005)。
- 第48周影像学进展:两个依那西普治疗组均少于甲氨蝶呤单药组。
关键数值与推荐
- ACR20应答定义为美国风湿病学会20%改善标准。
- MDA应答定义为最小疾病活动度达标。
- 其他次要结局包括ACR50、ACR70、极低疾病活动度评分和PsA疾病活动评分,组间差异与主要及关键次要终点结果一致。
临床怎么用
- 对于银屑病关节炎患者,依那西普单药或联合甲氨蝶呤可作为优于甲氨蝶呤单药的治疗选择。
- 联合甲氨蝶呤并未整体优于依那西普单药,决策时需结合患者具体情况。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
OBJECTIVE: To examine the efficacy of methotrexate monotherapy relative to etanercept monotherapy and the value of combining methotrexate and etanercept for the treatment of patients with psoriatic arthritis (PsA). METHODS: In this double-blind study, 851 patients with PsA were randomized to 1 of 3 treatment arms, as follows: oral methotrexate (20 mg) plus subcutaneous placebo given weekly (n = 284), subcutaneous etanercept (50 mg) plus oral placebo given weekly (n = 284), or subcutaneous etanercept (50 mg) plus oral methotrexate (20 mg) given weekly (combination therapy; n = 283). The American College of Rheumatology 20% improvement (ACR20) response and Minimal Disease Activity (MDA) response at week 24 were the primary end point and key secondary end point, respectively. Other measures of inflammatory arthritis, radiographic progression, and nonarticular disease manifestations were also assessed. RESULTS: Patients with PsA had a mean ± SD age of 48.4 ± 13.1 years, and the mean ± SD duration of PsA was 3.2 ± 6.3 years (median 0.6 years). ACR20 and MDA response rates at week 24 were significantly greater in patients who received etanercept monotherapy compared with those who received methotrexate monotherapy (ACR20, 60.9% versus 50.7% of patients [P = 0.029]; MDA, 35.9% versus 22.9% of patients [P = 0.005]), and both were significantly greater in the combination therapy group compared with the methotrexate monotherapy group at week 24 (ACR20, 65.0% versus 50.7% of patients [P = 0.005]; MDA, 35.7% versus 22.9% of patients [P = 0.005]). Other secondary outcomes (ACR50 and ACR70 response rates, proportions of patients achieving a Very Low Disease Activity score, and PsA disease activity scores) showed between-group differences that were consistent with the primary and key secondary end point results. Furthermore, patients in both etanercept treatment arms showed less radiographic progression at week 48 compared with patients who received methotrexate monotherapy. Outcomes were similar in the combination therapy and etanercept monotherapy groups, except for some skin end points. No new safety signals were seen. CONCLUSION: Etanercept monotherapy and combination therapy with etanercept and methotrexate showed greater efficacy than methotrexate monotherapy in patients with PsA, according to the ACR and MDA response rates and extent of radiographic progression at follow-up. Overall, combining methotrexate and etanercept did not improve the efficacy of etanercept.
引用
- Mease PJ, Gladman DD, Collier DH, et al. Etanercept and Methotrexate as Monotherapy or in Combination for Psoriatic Arthritis: Primary Results From a Randomized, Controlled Phase III Trial. Arthritis Rheumatol. 2019. PMID: 30747501. doi:10.1002/art.40851
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。